Cocrystal Pharma, Inc.OTCQB
Cocrystal Pharma - Overhyped Biotech Or The Next Pharmasset?
BioTech Horizons • 59 Comments
BioTech Horizons • 59 Comments
Wed, Nov. 9, 8:43 AM
Fri, Sep. 2, 8:26 AM| Fri, Sep. 2, 8:26 AM | 10 Comments
Wed, Aug. 10, 6:44 AM
Fri, Jul. 22, 8:23 AM| Fri, Jul. 22, 8:23 AM | 11 Comments
Tue, Mar. 8, 9:13 AM
- Sydney, Australia-based Benitec (NASDAQ:BNTC) announces that its DNA-directed RNA interference (ddRNAi) candidate, BB-HB-331, showed robust and durable hepatitis B virus (HBV) suppression in vivo following a single administration.
- The HBV suppression activity of BB-HB-331 was assessed in the Phoenix mouse model in which murine liver cells were replaced by human hepatocytes which made them susceptible to HBV infection. Once infected, the mice received a single systemic injection of BB-HB-331. Serum antigen levels, HBV viral proteins and extracellular HBV DNA were measured once per week for the duration of the eight-week study.
- Results showed a 1.83 log knockdown of serum HBV DNA, equivalent to a 98.5% reduction of circulating HBV. In addition, intracellular HBV DNA was reduced 94.9% while HBV surface antigen (HBsAg) and e antigen (HBeAg) were reduced by 97.6% and 92.6%, respectively. The results validated the previously reported in vitro findings.
- BB-HB-331 combines the gene silencing of RNA interference with the therapeutic potential of gene therapy. It is comprised of an AAV8 capsid (protein shell of a virus) and recombinant DNA engineered to express three short hairpin RNAs that target and inhibit viral RNA expressed from three regions across multiple HBV genotypes. The company plans to advance BB-HB-331 to clinical development.
- Previously: Benitec Biopharma's ddRNAi therapeutic candidate shows potent anti-HBV antigen activity in preclinical testing; shares up 14% (Dec. 7, 2015)
- HBV-related tickers: (NASDAQ:GILD)(OTCQB:COCP)(NYSE:GSK)(NASDAQ:IONS)(NASDAQ:DVAX)(NYSE:JNJ)(NASDAQ:ARWR)(NYSE:MRK)(NASDAQ:CTRV)(NASDAQ:ABUS)(NYSE:SNY)(NASDAQ:ALNY)(NYSE:BMY)
- Update: Shares up 26% in early trading.
Wed, Feb. 10, 9:07 AM
- Cocrystal Pharma (OTCQB:COCP) licenses certain patents and know-how from Duke and Emory Universities related to CRISPR-Cas9 technologies, a new gene editing method that many observers believe may finally deliver functional cures to many genetic disorders. The company's aim in this case, though, is to develop a cure for hepatitis B virus (HBV) infection and human papilloma virus (HPV) infection.
- CRISPR-Cas9 is the "next big thing" in biotech because of its unprecedented precision in editing DNA. CRISPR, the acronym for "clustered, regularly interspaced short palindromic repeats," uses RNA to guide the molecular scissors, the Cas9 enzyme, to a specific DNA sequence where it makes a specific cut in the DNA and triggers the cell's DNA repair machinery to address the genetic defect. In other words, its can precisely cut out a mutated section of DNA and replace it with one that functions properly.
- Financial terms are not disclosed.
Nov. 25, 2014, 12:59 PM
- The merger between Cocrystal Pharma (OTCQB:COCP +10.9%) and RFS Pharma, LLC has closed. The shareholders of each company will each own ~50% of combined entity.
- The merged organization will have a broad pipeline of products in hepatitis, influenza, rhinovirus, dengue fever and norovirus.
- Dr. Gary Wilcox will be CEO and Co-Chairman of the new firm. RFS Founder and Chairman Dr. Raymond F. Schinazi will be the other Co-Chairman.
Aug. 15, 2014, 8:17 AM
May 16, 2014, 9:07 AM